Tumor microenvironment

What have we learned studying the immune response in this puzzling battlefield?

Simone Mocellin, Monica Panelli, Ena Wang, Carlo Riccardo Rossi, Francesco M. Marincola

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Recent developments hallmark the progress in the understanding of tumor immunology and related therapeutic strategies. The administration of interleukin-2 (IL-2) to patients with cancer has shown that immune manipulation can mediate the regression of established cancers. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing against these antigens has opened new avenues for the development of active immunization of patients with cancer. However, an efficient immune response against tumor comprises an intricate molecular network still poorly understood. Only when the code governing immune responsiveness of cancer will be deciphered, new therapeutic strategies could be designed to fit biologically defined mechanisms of immune rejection of cancer. In this review, we propose that the mechanisms regulating tumor rejection in response to vaccination will be more efficiently identified by following the evolution of treatment induced events within the tumor microenvironment taking advantage of recently developed technological tools. As a model, we will discuss the observed immune response to tumor antigen-specific immunization and its relationship with the systemic administration of IL-2.

Original languageEnglish
Pages (from-to)437-444
Number of pages8
JournalTumori
Volume88
Issue number6
Publication statusPublished - Nov 2002
Externally publishedYes

Fingerprint

Tumor Microenvironment
Neoplasms
Interleukin-2
Vaccination
Antigens
Neoplasm Genes
Neoplasm Antigens
Allergy and Immunology
Immunization
Therapeutics

Keywords

  • Immunotherapy
  • Melanoma
  • Microenvironment
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research

Cite this

Mocellin, S., Panelli, M., Wang, E., Rossi, C. R., & Marincola, F. M. (2002). Tumor microenvironment: What have we learned studying the immune response in this puzzling battlefield? Tumori, 88(6), 437-444.

Tumor microenvironment : What have we learned studying the immune response in this puzzling battlefield? / Mocellin, Simone; Panelli, Monica; Wang, Ena; Rossi, Carlo Riccardo; Marincola, Francesco M.

In: Tumori, Vol. 88, No. 6, 11.2002, p. 437-444.

Research output: Contribution to journalReview article

Mocellin, S, Panelli, M, Wang, E, Rossi, CR & Marincola, FM 2002, 'Tumor microenvironment: What have we learned studying the immune response in this puzzling battlefield?', Tumori, vol. 88, no. 6, pp. 437-444.
Mocellin, Simone ; Panelli, Monica ; Wang, Ena ; Rossi, Carlo Riccardo ; Marincola, Francesco M. / Tumor microenvironment : What have we learned studying the immune response in this puzzling battlefield?. In: Tumori. 2002 ; Vol. 88, No. 6. pp. 437-444.
@article{83c4f0d8a69c4946ab19298a38f5314f,
title = "Tumor microenvironment: What have we learned studying the immune response in this puzzling battlefield?",
abstract = "Recent developments hallmark the progress in the understanding of tumor immunology and related therapeutic strategies. The administration of interleukin-2 (IL-2) to patients with cancer has shown that immune manipulation can mediate the regression of established cancers. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing against these antigens has opened new avenues for the development of active immunization of patients with cancer. However, an efficient immune response against tumor comprises an intricate molecular network still poorly understood. Only when the code governing immune responsiveness of cancer will be deciphered, new therapeutic strategies could be designed to fit biologically defined mechanisms of immune rejection of cancer. In this review, we propose that the mechanisms regulating tumor rejection in response to vaccination will be more efficiently identified by following the evolution of treatment induced events within the tumor microenvironment taking advantage of recently developed technological tools. As a model, we will discuss the observed immune response to tumor antigen-specific immunization and its relationship with the systemic administration of IL-2.",
keywords = "Immunotherapy, Melanoma, Microenvironment, Vaccination",
author = "Simone Mocellin and Monica Panelli and Ena Wang and Rossi, {Carlo Riccardo} and Marincola, {Francesco M.}",
year = "2002",
month = "11",
language = "English",
volume = "88",
pages = "437--444",
journal = "Tumori",
issn = "0300-8916",
publisher = "Wichtig Publishing",
number = "6",

}

TY - JOUR

T1 - Tumor microenvironment

T2 - What have we learned studying the immune response in this puzzling battlefield?

AU - Mocellin, Simone

AU - Panelli, Monica

AU - Wang, Ena

AU - Rossi, Carlo Riccardo

AU - Marincola, Francesco M.

PY - 2002/11

Y1 - 2002/11

N2 - Recent developments hallmark the progress in the understanding of tumor immunology and related therapeutic strategies. The administration of interleukin-2 (IL-2) to patients with cancer has shown that immune manipulation can mediate the regression of established cancers. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing against these antigens has opened new avenues for the development of active immunization of patients with cancer. However, an efficient immune response against tumor comprises an intricate molecular network still poorly understood. Only when the code governing immune responsiveness of cancer will be deciphered, new therapeutic strategies could be designed to fit biologically defined mechanisms of immune rejection of cancer. In this review, we propose that the mechanisms regulating tumor rejection in response to vaccination will be more efficiently identified by following the evolution of treatment induced events within the tumor microenvironment taking advantage of recently developed technological tools. As a model, we will discuss the observed immune response to tumor antigen-specific immunization and its relationship with the systemic administration of IL-2.

AB - Recent developments hallmark the progress in the understanding of tumor immunology and related therapeutic strategies. The administration of interleukin-2 (IL-2) to patients with cancer has shown that immune manipulation can mediate the regression of established cancers. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing against these antigens has opened new avenues for the development of active immunization of patients with cancer. However, an efficient immune response against tumor comprises an intricate molecular network still poorly understood. Only when the code governing immune responsiveness of cancer will be deciphered, new therapeutic strategies could be designed to fit biologically defined mechanisms of immune rejection of cancer. In this review, we propose that the mechanisms regulating tumor rejection in response to vaccination will be more efficiently identified by following the evolution of treatment induced events within the tumor microenvironment taking advantage of recently developed technological tools. As a model, we will discuss the observed immune response to tumor antigen-specific immunization and its relationship with the systemic administration of IL-2.

KW - Immunotherapy

KW - Melanoma

KW - Microenvironment

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0036879920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036879920&partnerID=8YFLogxK

M3 - Review article

VL - 88

SP - 437

EP - 444

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -